Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19

This study found that Fluvoxamine, a drug used for psychiatric conditions with anti-inflammatory properties, did not reduce recovery time in patients with symptomatic mild to moderate COVID-19. These findings are important because it advances research into oral treatments for COVID-19 and directs clinicians to other avenues of treatment. Co-author Mario Castro, MD, MPH serves on the Lung Association Scientific Advisory Committee and is an ACRC investigator.
Freedom From Smoking Clinic
Detroit, MI | May 29, 2024
Asthma Basics Workshop - National
, | Jun 18, 2024